ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
Neoadjuvant treatment followed by surgery results in longer event-free survival for resectable, macroscopic stage III melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.